for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Recordati SpA

RECI.MI

Latest Trade

38.69EUR

Change

0.44(+1.15%)

Volume

93,532

Today's Range

38.25

 - 

38.80

52 Week Range

27.70

 - 

41.06

As of on the Italian SE (Mercato Continuo Italia) ∙ Minimum 15 minute delay

Pricing

Previous Close
38.25
Open
38.49
Volume
93,532
3M AVG Volume
8.46
Today's High
38.80
Today's Low
38.25
52 Week High
41.06
52 Week Low
27.70
Shares Out (MIL)
205.21
Market Cap (MIL)
7,986.49
Forward P/E
23.88
Dividend (Yield %)
2.30

Next Event

Q3 2019 Recordati Industria Chimica e Farmaceutica SpA Earnings Release

Latest Developments

More

Recordati H1 Net Profit Up At EUR 174.3 Mln, Updates 2019 Guidance

Recordati To Acquire Worldwide Rights To Signifor And Osilodrostat (LCI699)

Recordati Q1 Net Income Up 6.4 Pct At EUR 92.1 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Recordati SpA

Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The Company owns and operates through Natural Point srl also in the food supplement sector.

Industry

Major Drugs

Contact Info

Via M. Civitali, 1

+39.02.487871

http://www.recordati.com

Executive Leadership

Flemming Ornskov

Chairman of the Board

Andrea Recordati

Chief Executive Officer, Executive Director

Alfredo Altavilla

Vice Chairman of the Board

Fritz Squindo

Chief Financial Officer, Financial Reporting Officer, Managing Director, Executive Director

Corrado Castellucci

Executive Vice President - Rare Diseases Business Unit

Key Stats

2.63 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

1.2K

2017

1.3K

2018

1.4K

2019(E)

1.5K
EPS (EUR)

2016

1.135

2017

1.381

2018

1.494

2019(E)

1.599
Price To Earnings (TTM)
24.77
Price To Sales (TTM)
5.71
Price To Book (MRQ)
7.32
Price To Cash Flow (TTM)
20.58
Total Debt To Equity (MRQ)
67.45
LT Debt To Equity (MRQ)
58.60
Return on Investment (TTM)
19.42
Return on Equity (TTM)
15.41

Latest News

BRIEF-Recordati FY Prelim. Net Profit Up 21.6 Pct At EUR 288.8 Mln

* FY PRELIM NET REVENUES EUR 1,288.1 MILLION, UP 11.6 PERCENT YEAR ON YEAR

BRIEF-Recordati Q3 net profit up at EUR 72.8 mln, confirms FY targets

* Q3 NET PROFIT EUR 72.8 MILLION VERSUS EUR 59.6 MILLION YEAR AGO

BRIEF-Recordati: European Commission approves Reagila as schizophrenia treatment

* EUROPEAN COMMISSION APPROVES REAGILA (CARIPRAZINE) FOR TREATMENT OF SCHIZOPHRENIA Source text: http://bit.ly/2teBSwQ Further company coverage: (Gdynia Newsroom)

BRIEF-Recordati signs exclusive license agreement with MimeTech

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA:

AstraZeneca sells aging beta-blocker to Recordati for $300 million

AstraZeneca <AZN.L> has sold the European rights to its aging beta-blocker heart drug Seloken to Italy's Recordati <RECI.MI> for $300 million, as part of a continuing drive by the British drugmaker to spin off non-core assets.

BRIEF-Italy's Recordati sees 2019 sales at around 1.45 bln euros

* sees 2019 sales at around 1.45 billion euros Source text for Eikon: Further company coverage: (Reporting by Milan newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up